印尼国家疫苗制造者PT Bio Farma(PT Bio Farma)领导一个关键网络,并于2020年生产第一支世卫组织核准的NOPV2脊髓灰质炎疫苗,从而推进全球公平。 PT Bio Farma, Indonesia’s state vaccine maker, advanced global equity by leading a key network and producing the first WHO-approved nOPV2 polio vaccine in 2020.

印度尼西亚国有疫苗制造者PT Pio Farma作为发展中国家疫苗制造商网络的创始成员和2023-2025年主席,推动全球疫苗公平,支持疫苗自力更生和通过伙伴关系、技术转让和创新获取疫苗。 Indonesia’s state-owned vaccine maker PT Bio Farma has advanced global vaccine equity as a founding member and 2023–2025 chair of the Developing Countries Vaccine Manufacturers’ Network, supporting vaccine self-reliance and access through partnerships, technology transfers, and innovation. 世卫组织在2020年生产世卫组织首个紧急使用清单NOPV2脊髓灰质炎疫苗方面发挥了关键作用,并保持了超过35亿剂量的年度生产能力,从而加强了其全球卫生领导力。 It played a key role in producing the first WHO Emergency Use Listed nOPV2 polio vaccine in 2020 and maintains annual production capacity exceeding 3.5 billion doses, reinforcing its global health leadership.